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Practical recommendations for the management of diabetes 
in patients with COVID-19
Stefan R Bornstein, Francesco Rubino, Kamlesh Khunti, Geltrude Mingrone, David Hopkins, Andreas L Birkenfeld, Bernhard Boehm, 
Stephanie Amiel , Richard IG Holt, Jay S Skyler, J Hans DeVries, Eric Renard, Robert H Eckel, Paul Zimmet,  Kurt George Alberti, Josep Vidal, 
Bruno Geloneze, Juliana C Chan, Linong Ji, Barbara Ludwig
Diabetes is one of the most important comorbidities linked to the severity of all three known human pathogenic 
coronavirus infections, including severe acute respiratory syndrome coronavirus 2. Patients with diabetes have an 
increased risk of severe complications including Adult Respiratory Distress Syndrome and multi-organ failure. 
Depending on the global region, 20–50% of patients in the coronavirus disease 2019 (COVID-19) pandemic had 
diabetes. Given the importance of the link between COVID-19 and diabetes, we have formed an international panel of 
experts in the field of diabetes and endocrinology to provide some guidance and practical recommendations for the 
management of diabetes during the pandemic. We aim to briefly provide insight into potential mechanistic links 
between the novel coronavirus infection and diabetes, present practical management recommendations, and elaborate 
on the differential needs of several patient groups.
Introduction
From January, 2020, we have been facing an 
unprecedented outbreak of coronavirus disease 2019 
(COVID-19) caused by a novel coronavirus, severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2),which 
has now become a global catastrophe. Data from the 
early months of 2020 suggest that most people with 
COVID-19 have comorbidities, the most prevalent of 
which are diabetes, cardiovascular disease, and 
hypertension.1 A significant association with worse 
outcomes is seen in people with these comorbidities.1 
Studies have also shown that COVID-19 is associated 
with hyperglycaemia particularly in the elderly with 
type 2 diabetes.2 In view of many uncertainties with 
COVID-19, a faculty of representatives from primary and 
specialist care have developed a consensus document on 
the management of diabetes for people at risk of or with 
confirmed COVID-19 for use in both primary and 
specialist care. The brief practical recommendations 
authored by this group were convened virtually. The 
recommendations are based on queries that have been 
emphasised to be important by clinicians, questions that 
have been raised by colleagues and social media, and 
recommendations guided by using focused-literature 
review. Clinical decision making in the manage ment of 
diabetes is already complex and in normal circumstances 
we recommend clinicians follow guidelines for 
management of people with diabetes. However, the 
recommendations authored by our group add to the 
existing guidelines by considering specific points for the 
management of patients with diabetes and COVID-19 
disease or at risk for metabolic disease.
The potential links between diabetes and 
COVID-19 infection
Diabetes is a primary risk factor for the development of 
severe pneumonia and a septic course due to virus 
infections and occurs in around 20% of patients.3,4 
Diabetes was identified as a major contributor to disease 
severity and mortality in Middle East Respiratory 
Syndrome (MERS-CoV).5 Evidence from epidemiological 
observations in regions heavily affected by SARS-CoV-2 
and reports from the Centers for Disease Control and 
Prevention (CDC) and other national health centres and 
hospitals showed that the risk of a fatal outcome from 
COVID-19 is up to 50% higher in patients with diabetes 
than in those who do not have diabetes.6 There are several 
hypotheses to explain the increased incidence and 
severity of COVID-19 infection in people with diabetes. 
In general, people with all forms of diabetes are at 
increased risk of infection because of defects in innate 
immunity affecting phagocytosis, neutrophil chemotaxis, 
and cell-mediated immunity; however, the high 
frequency of diabetes in serious cases of COVID-19 could 
potentially reflect the higher prevalence of type 2 diabetes 
in older people. Furthermore, diabetes in older age is 
associated with cardiovascular disease, which in itself 
could help to explain the association with fatal outcomes 
of COVID-19.
There are at least two specific mechanisms that might 
play a role in COVID-19 infection. First, to gain entry to 
its target cells, the SARS-CoV-2 virus hijacks an 
endocrine pathway that plays a crucial role in blood 
pressure regulation, metabolism, and inflammation.7 
Angiotensin-converting-enzyme 2 (ACE2) has been 
identified as the receptor for the coronavirus spike 
protein. ACE2 has protective effects primarily regarding 
inflammation. COVID-19 infection reduces ACE2 
expression inducing cellular damage, 
hyperinflammation, and respiratory failure.7 Acute 
hyperglycaemia has been shown to upregulate ACE2 
expression on cells which might facilitate viral cell entry. 
However, chronic hyperglycaemia is known to 
downregulate ACE2 expression making the cells 
vulnerable to the inflammatory and damaging effect of 
the virus. Furthermore, the expression of ACE2 on 
pancreatic β cells can lead to a direct effect on β cell 
function.8–10 Although these findings have not been 
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verified in humans, they suggest that diabetes might not 
only be a risk factor for a severe form of COVID-19 
disease but also that infection could induce new onset 
diabetes.8–10 Potential β cell damage caused by the virus 
leading to insulin deficiency is supported by the 
observation of Italian colleagues and co-authors of these 
recommen dations who have reported frequent cases of 
severe diabetic ketoacidosis (DKA) at the time of hospital 
admission. Another important observation by the co-
authors from various centres in different countries 
affected by COVID-19 is the tremendous insulin require-
ment in patients with a severe course of the infection. To 
what extent COVID-19 plays a direct role in this high 
insulin resistance is unclear. According to the personal 
experiences of co-authors of this Personal View, the 
extent of insulin resistance in patients with diabetes 
seems dispro portionate compared with critical illness 
caused by other conditions.
A second potential mechanism that might explain the 
link between COVID-19 and diabetes involves the 
dipeptidyl peptidase-4 (DPP-4) enzyme, which is 
commonly targeted pharmacologically in people with 
type 2 diabetes. In cell studies, DPP-4 was identified as a 
functional receptor for human coronavirus-Erasmus 
Medical Center (hCoV-EMC), the virus responsible for 
MERS.11 Antibodies directed against DPP-4 inhibited 
hCoV-EMC infection of primary cells. DPP-4 enzyme is 
an ubiquitously expressed type II transmembrane glyco-
protein. It plays a major role in glucose and insulin 
metabolism but also increases inflammation in type 2 
diabetes.12 Whether these mechanisms also apply to 
COVID-19 and whether diabetes treatment with DPP-4 
inhibitors in clinical practice influences the course of 
the infection is currently unknown, but, if these 
mechanisms translate to SARS-CoV-2, the use of these 
agents could reduce DPP-4 concentrations and could 
provide thera peutic opportunities for treatment of 
COVID-19.12
Implications on diabetes management 
The clinical relevance of the aforementioned mechanisms 
is currently uncertain, but health-care practitioners 
should be aware of their implications for patients with 
diabetes. We have compiled a simple flowchart for the 
metabolic screening and management of patients with 
COVID-19 and diabetes or at risk for metabolic disease. 
This includes recommendations regarding both the need 
for primary prevention of diabetes as well as the avoidance 
of severe sequelae of diabetes triggered by unidentified or 
poorly managed diabetes (figure). Furthermore, special 
considerations on anti-diabetes drugs commonly used in 
patients with type 2 diabetes in view of COVID-19 are 
presented in the panel.
Metabolic and glycaemic control
People with diabetes who have not yet been infected with 
the SARS-CoV-2 virus should intensify their metabolic 
control as needed as means of primary prevention of 
COVID-19 disease. This includes continuation and strict 
abidance with adequate control of blood pressure and 
lipids. Wherever possible, remote consultations using 
Connected Health models should be utilised to reduce 
exposure. They should also be encouraged to follow 
general advice from WHO, the CDC, and state and local 
governments about hand washing and physical distancing.
All patients without diabetes and particularly when at 
high risk for metabolic disease who have contracted the 
viral infection need to be monitored for new onset 
diabetes that might be triggered by the virus. All patients 
with COVID-19 disease and diabetes require continuous 
and reliable glycaemic control as suggested in the 
flowchart.
Figure: Flowchart for metabolic screening and type 1 and 2 diabetes management of patients with COVID-19
Older patients  refers to those aged 70 and above. ARDS=Acute Respiratory Distress Syndrom. CGM=Continous Glucose Measurement. FGM=Flash Glucose 
Measurement. HbA1c=haemoglobin A1c. TIR=time in range. *Target concentrations for lower plasma glucose can be adjusted to 5 mmol/l (90 mg/dl) in frail patients. 
†HbA1c testing might not be possible at the time, but previous measurements if available allow for differentiation of chronic and acute decompensation.
Prevention of infection in diabetes
• Sensitisation of patients with diabetes for the importance of optimal metabolic 
   control
• Optimisation of current therapy if appropriate
• Caution with premature discontinuation of established therapy
• Utilisation of Telemedicine and Connected Health models if possible to 
   maintain maximal self containment
• Plasma glucose concentration: 4–8 mmol/L (72–144 mg/dL)*
• HbA
1c
:† less than 53 mmol/mol (7%)
• CGM/FGM targets 
  • TIR (3·9–10 mmol/L): more than 70% (>50% in frail and older people)
  • Hypoglycaemia (<3·9 mmol/L): less than 4% (<1% in frail and older people)
• Plasma glucose concentration: 4–10 mmol/L (72–180 mg/dL)*
• Plasma glucose monitoring, electrolytes, pH, blood ketones, or 
   β-hydroxybutyrate
• Liberal indication for early intravenous insulin therapy in severe courses  
   (ARDS, hyperinflammation) for exact titration, avoiding variable 
   subcutaneous resorption, and management of commonly seen very high 
   insulin consumption 
Monitor for new onset diabetes in
infected patients (in-patient care)
Management of infected patients 
with diabetes (intensive care unit)
In-patient or intensive care unit
Consensus recommendations for COVID-19 and metabolic disease
Therapeutic aims
Out-patient care
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Management of hyperglycaemia and associated 
metabolic conditions
Most patients with type 2 diabetes have other components 
of the metabolic syndrome including hypertension and 
dyslipidaemia. Therefore, continuation with an appropriate 
antihypertensive and lipid-lowering regimen in all these 
patients is of crucial importance.
Treatment with ACE inhibitors and angiotensin 2 
receptor blockers could increase the expression of ACE2, 
which could accelerate the entry of the virus into the cells.13 
However, as SARS-CoV-2 might impair the protective 
ACE2/Mas receptor pathway and increase deleterious 
angiotensin-2 activity, the use of ACE inhibitors and 
angiotensin 2 receptor blockers could protect against 
severe lung injury following infection. On the basis of 
currently available evidence, we recommend that patients 
should continue with their antihypertensive regimens 
including ACE inhibitors and angiotensin 2 receptors. 
This view is endorsed by a recent position statement from 
the European Society of Cardiology and the Heart Failure 
Society of America, American College of Cardiology, 
American Heart Association, who strongly recommended 
continuation of treatment with ACE inhibitors and 
angiotensin 2 receptor blockers.14
Statins have been shown to restore the reduction of 
ACE2 induced by high lipids such as low density 
lipoprotein or lipoprotein(a).15 The pleiotropic anti-inflam-
matory effects of statins have been attributed to the 
upregulation of ACE2. However, although we believe that 
modulation of ACE2 expression is associated with both 
infection and mortality rates in COVID-19, statins should 
not be discontinued because of the long-term benefits and 
the potential for tipping the balance towards a cytokine 
storm by rebound rises in interleukin(IL)-6 and IL-1ß if 
they were to be discontinued. Given the close links between 
diabetes and cardiovascular disease, we recommend 
control of lipid concentrations in all patients with 
COVID-19.
There are certain subgroups of people with diabetes 
who might require specific consideration. Elevated 
hemo globin A1c in people with type 1 diabetes 
compromises immune function rendering them more 
susceptible to any infectious disease. These individuals 
will need more intense monitoring and supportive 
therapy to reduce the risk of metabolic decompensation 
including DKA, in particular for those taking sodium 
glucose co-transporter 2 inhibitors (SGLT2). According to 
the expertise from the co-authors, an increase in the 
prevalence of severe DKA in COVID-19 positive patients 
with established type 1 diabetes has been observed, but 
this might in part be because of delayed hospital 
admission. Thus, making patients with type 1 diabetes 
aware of this complication and re-educating them about 
typical symptoms, home-measurement of urine or blood 
ketones, acute behaviour guidelines, and liberal and early 
inquiry of professional medical advice and sick day rules 
is crucial. Patients who have undergone transplantation 
of islets, pancreas or kidney, or those on immuno-
suppressive therapy will be at particularly increased risk; 
additionally, the potential effect of coronavirus infection 
on pancreatic function in this group is unknown and 
monitoring for a recurrence of insulin requirement in 
those who are insulin independent after their transplant 
is important.
The increasing number of patients with type 2 diabetes 
and concomitant fatty liver disease will probably have an 
increased risk for a more pronounced inflammatory 
response including the so-called cytokine storm, and these 
patients should be considered at increased risk of severe 
COVID-19 disease. Therefore, screening for hyper-
inflammation using laboratory trends (eg, increasing 
ferritin, decreasing platelet counts, high-sensitivity 
C-reactive protein, or erythrocyte sedimentation rate) are 
of crucial importance and might also help to identify 
subgroups of patients for whom immuno suppression 
(steroids, immunoglobulins, selective cytokine blockade) 
could improve the outcome.
The majority of patients with type 2 diabetes are living 
with conditions of overweight or obesity. Body mass index 
Panel: Consideration of potential metabolically interfering effects of drugs in 
suspected or COVID-19 positive patients with type 2 diabetes
Metformin
• Dehydration and lactic acidosis will probably occur if patients are dehydrated, so 
patients should stop taking the drug and follow sick day rules
• During illness, renal function should be carefully monitored because of the high risk of 
chronic kidney disease or acute kidney injury
Sodium-glucose-co-transporter 2 inhibitors
• These include canagliflozin, dapagliflozin, and empagliflozin
• Risk of dehydration and diabetic ketoacidosis during illness, so patients should stop 
taking the drugs and follow sick day rules
• Patients should avoid initiating therapy during respiratory illness
• Renal function should be carefully monitored for acute kidney injury
Glucagon-like peptide-1 receptor agonists
• These include albiglutide, dulaglutide, exenatide-extended release, liraglutide, 
lixisenatide, and semaglutide
• Dehydration is likely to lead to a serious illness so patients should be closely monitored
• Adequate fluid intake and regular meals should be encouraged
Dipeptidyl peptidase-4 inhibitors
• These include alogliptin, linagliptin, saxagliptin, and sitagliptin
• These drugs are generally well tolerated and can be continued
Insulin
• Insulin therapy should not be stopped
• Regular self-monitoring of blood-glucose every 2–4 hours should be encouraged, or 
continuous glucose monitoring
• Carefully adjust regular therapy if appropriate to reach therapeutic goals according to 
diabetes type, comorbidities, and health status
Connected Health models and Telemedicine should be used to continue regular reviews 
and self-management education programmes virtually and ensure patients are adherent 
to therapy.
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is an important determinant of lung volume, respiratory 
mechanics, and oxygenation during mechanical vent-
ilation, especially in the supine position. Therefore, 
patients with obesity and diabetes could be at specific risk 
of ventilatory failure and complications during mechanical 
ventilation. Clinical experience with young patients with 
obesity and COVID-19 supports this notion. Furthermore, 
individuals with obesity or with diabetes have an altered 
innate and adaptive immune response, characterised by a 
state of chronic and low-grade inflammation with higher 
concentrations of the pro-inflammatory leptin and lower 
anti-inflammatory adiponectin.16 Additionally, obesity is 
often associated with physical inactivity leading to aggra-
vated insulin resistance. This condition per se impairs 
immune response against microbial agents including 
macrophage activation and inhibition of pro-inflam-
matory cytokines and leads to a dysregulation of the 
immune response contributing to complications asso-
ciated with obesity.17
Furthermore, SARS-CoV-2 can induce long-term 
metabolic alterations in patients who have been infected 
with the virus, as has been reported previously with the 
SARS virus.18 Therefore, a careful cardiometabolic 
monitoring of patients who have survived severe 
COVID-19 disease might be necessary.
Importantly, we should also bring attention to the 
subgroup of people with diabetes who work as health-
care professionals. Given that COVID-19 might be more 
preva lent among the sick than is currently being 
diagnosed, health-care professionals with diabetes 
should be deployed away from front line clinical duties 
where possible. For cases in which this is not possible or 
desirable, high-grade protection or increased protection 
should be used.
Surgical treatment of type 2 diabetes—metabolic 
surgery
Provision of elective surgical procedures—including meta-
bolic surgery—is being postponed in many hospitals 
around the world to increase capacity for in-patient beds 
and acute care. However, postponing elective metabolic 
surgery during the outbreak of COVID-19 is advisable 
regardless of issues of hospital capacity. Patients with 
type 2 diabetes and obesity are at increased risk of 
complications of COVID-19,17 compounding the potential 
negative influence of surgical stress in the recovery period. 
Furthermore, although specific data are not available, there 
are plausible concerns that pneumoperitoneum and the 
use of haemostatic instruments during laparoscopy (by far 
the most common approach used in metabolic surgery 
because of its ability to reduce morbidity and mortality) 
might lead to viral aerosolisation, thus increasing the risk 
of transmission of the virus to both patients and staff.
Whether patients with type 2 diabetes who have had 
metabolic surgery will be protected from adverse 
outcomes of COVID-19 relative to their peers who have 
not undergone surgical treatment simply because of 
better glycaemic control remains unclear.19 However, 
metabolic surgery could induce nutritional deficiencies, 
including reduced absorption of vitamins and micro-
nutrients, which play important roles in the regulation of 
the immune and stress response.20 Although there are no 
data yet to suggest that patients who had metabolic 
surgery are at greater risk of infection or complications 
from COVID-19, these patients should receive particular 
attention and close monitoring.
Special considerations on use of diabetes drugs
Although optimising glycaemic control to reduce the risk 
of severe COVID-19 disease is important, specific 
considerations around treatment modality should be 
made (panel). Lactic acidosis associated with metformin, 
or euglycaemic or moderate hyperglycaemic diabetic 
ketoacidosis associated with SGLT-2 inhibitors are rare 
events; however, we recommend these drugs should be 
discontinued for patients with severe symptoms of 
COVID-19 to reduce the risk of acute metabolic 
decompensation.21 Importantly, discontinuing these drugs 
is not recommended prophylactically for out-patients with 
diabetes without any symptoms of infection or in the 
absence of evidence for a serious course of COVID-19. 
Furthermore, at present, no convincing evidence exists to 
suggest that DPP-4 inhibitors should be discontinued. 
Further analyses on affected patients with various diabetes 
treatments and COVID-19 could allow elucidation of the 
effects of DPP-4 inhibitors.12 Importantly, if drugs are 
discontinued, the alternative treatment of choice—in 
cases for which this option is feasible—is insulin.21
Given the multiple stresses associated with COVID-19 
including but not limited to respiratory failure, the 
defects in insulin secretion and the frequent occurrence 
of diarrhoea and sepsis, most patients will require 
Search strategy and selection criteria
We identified the references for this publication through 
searches of PubMed for articles published between 
Apr 29, 2009, and Apr 5, 2020, using combinations of the 
terms “coronavirus”, “COVID-19”, “SARS-CoV-2”, “nCoV”, 
“diabetes”, “risk factors”, “severe acute respiratory syndrome”, 
“acute respiratory distress syndrome”, and “co-morbidities”. 
We reviewed guidelines for the management of COVID-19 
published by WHO, American Diabetes Assiciation, and the US 
Centers for Disease Control and Prevention. We added articles 
through searches of the authors’ personal files. We also 
reviewed relevant references cited in retrieved articles. Articles 
published in English, Italian, and Chinese were included. 
The final reference list was generated on the basis of relevance 
to the topics covered in this publication, with the aim of 
emphasising the multiple challenges the health-care 
professionals from practitioners to intensive care staff might 
face in the management of patients with diabetes and at risk of 
or with COVID-19, and providing practical recommendations 
for the care of this vulnerable subgroup.
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insulin and especially since many cases are reported with 
very high insulin consumption, this will need to be 
managed by intravenous infusion.22 Considerable care is 
required in fluid balance as there is a risk that excess 
fluid can exacerbate pulmonary oedema in the severely 
inflamed lung. Furthermore, potassium balance needs to 
be considered carefully in the context of insulin treatment 
as hypokalaemia is a common feature in COVID-19 
(possibly associated with hyperaldosteronism induced by 
high concentrations of angiotensin 2) and could be 
exacerbated following initiation of insulin.22
We do realise that all our recommendations and 
reflections are based on our expert opinion, awaiting the 
outcome of randomised clinical trials. Executing clinical 
trials under challenging circumstances has been proven 
feasible during the COVID-19 pandemic, and trial net-
works to provide evidence-based therapies are arising.23 
Investigating subgroups with diabetes and how these 
relate to COVID-19 outcomes will be important, in 
particular investigating if some of the various manage-
ment approaches would be particularly effective in 
managing diabetes in a COVID-19 context.24
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